Dr Javier Cortes is head of breast cancer and gynecological cancers at Hospital Universitario Ramón y Cajal in Madrid, Spain, as well as Clinical Investigator in the breast cancer research program at Vall d’Hebron Institute of Oncology in Barcelona, Spain.
He is one of the European leaders in the field of HER2+ breast cancer, and has led fundamental trials that resulted in the approval of pertuzumab, eribulin and everolimus for metastatic breast cancer. He continues to actively participate in national and international clinical investigations to develop molecularly targeted therapies, such as CDK 4/6 inhibitors, and immunotherapies.
Dr Cortés is on the Scientific Committee of ESMO and is an active member of ASCO and the Spanish Society of Medical Oncology.